Congress moves to map hidden vulnerabilities in America's drug supply
H.R. 4191 — MAPS Act · Filed by Doris Matsui (D-CA) · 2 cosponsors · Introduced Jun 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Health and Human Services to create and maintain a list of essential medicines critical to national security and public health, assess the vulnerabilities in their supply chains, and map those supply chains using data analytics to identify risks. The bill requires federal agencies to coordinate, share information about drug manufacturing locations and production volumes, and report annually to Congress on supply chain vulnerabilities and shortages.
Why we flagged it
The bill's core mechanism is creating federal visibility into drug supply chains through mapping, risk assessment, and inter-agency coordination. It is fundamentally a transparency and coordination measure aimed at identifying and mitigating national security and public health risks.
What the text implies
- The bill grants HHS broad authority to determine which medicines are 'essential' and at 'high risk,' potentially enabling future administrations to expand the list beyond current scope without additional legislative action.
- Information sharing among federal agencies about manufacturing locations and production volumes, while protected from FOIA disclosure, may create a centralized database of sensitive pharmaceutical infrastructure that could become a target for foreign intelligence or cyberattack if security measures fail.
The full analysis lists 4 implications of this text.
Who stands to gain
domestic pharmaceutical manufacturers; contract manufacturing organizations (CMOs); advanced manufacturing technology providers